Unknown

Dataset Information

0

Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8+ T cells.


ABSTRACT: The dendritic cell (DC) is the foremost antigen-presenting cell (APC) for ex vivo expansion of tumour-specific patient T cells. Despite marked responses in some patients following reinfusion of DC-activated autologous or HLA-matched donor T cells, overall response rates remain modest in solid tumours. Furthermore, most studies aim to generate immune responses against defined tumour-associated antigens (TAA), however, meta-analysis reveals that those approaches have less clinical success than those using whole tumour cells or their components. Tumour lysate (TL) is used as a source of tumour antigen in clinical trials and potentially represents the full range of TAAs in an undefined state. Little is known about how different APCs cooperate to present TL antigens. We examined the effect of oxidised whole-cell lysate (ox-L) versus soluble fraction freeze-thaw lysate (s-L) on bone marrow-derived DCs and macrophages, and magnetic bead-isolated splenic B cells. The APCs were used individually, or in combination, to prime T cells. CD8+ T cells produced interferon (IFN)-? in response to both s-L and ox-L, but only proliferated in response to ox-L. IFN-? production and proliferation was enhanced by priming with the DC+B cell combination. Compared to DC alone, a trend toward greater interleukin (IL)-12 production was observed when DC+B cell were loaded with s-L and ox-L antigens. CD8+ T-cell specific lysis in vivo was greatest in ox-L-primed groups and DC+B cell priming significantly increased in vivo cytotoxicity compared to DC alone. These improved T-cell responses with two APCs and stressed cell lysate has implications for APC-based adoptive cell therapies.

SUBMITTER: Grant ML 

PROVIDER: S-EPMC5539416 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Combining dendritic cells and B cells for presentation of oxidised tumour antigens to CD8<sup>+</sup> T cells.

Grant Melanie L ML   Shields Nicholas N   Neumann Silke S   Kramer Katrin K   Bonato Andrea A   Jackson Christopher C   Baird Margaret A MA   Young Sarah L SL  

Clinical & translational immunology 20170707 7


The dendritic cell (DC) is the foremost antigen-presenting cell (APC) for <i>ex vivo</i> expansion of tumour-specific patient T cells. Despite marked responses in some patients following reinfusion of DC-activated autologous or HLA-matched donor T cells, overall response rates remain modest in solid tumours. Furthermore, most studies aim to generate immune responses against defined tumour-associated antigens (TAA), however, meta-analysis reveals that those approaches have less clinical success t  ...[more]

Similar Datasets

| S-EPMC5154939 | biostudies-literature
| S-EPMC5540487 | biostudies-other
| S-EPMC6533917 | biostudies-literature
| S-EPMC6444187 | biostudies-literature
| S-EPMC5461099 | biostudies-literature
| S-EPMC2947393 | biostudies-literature
| S-EPMC6820535 | biostudies-literature
| S-EPMC5949331 | biostudies-literature
| S-EPMC5838096 | biostudies-literature
| S-EPMC5691066 | biostudies-literature